Tarsus Pharmaceuticals, Inc. (TARS)

NMS – Real vaqt narxi. Valyuta: USD

62.92

-1.42 (-2.21%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

62.92

0.00 (0.00%)

Bozordan keyin: Jun 26, 2026, 5:27 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Tarsus Pharmaceuticals, Inc. (TARS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates

Videolar

No Data

Press-relizlar

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

Search stocks

Tarsus Pharmaceuticals, Inc. (TARS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates

Videolar

No Data

Press-relizlar

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus